EN DE
Watch Spineway for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Spineway (ALSPW) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Spineway stock €0.17, price €0.10, upside +77.8%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR001400BVK2

S Spineway logo Thin data Nov 12, 2026

Spineway

ALSPW · PA

Cheap (44% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value €0.1743 · Strongly undervalued 
Low debt 
Even on cautious assumptions the value is 21% above the price (€0.1182). 
Quality 48/100 
Expensive Growth (revenue 5y +29.8 %/yr in EUR) 
Mixed vs. peers (4/10) 
Falling price (downtrend) 
Loss-making · -18.2% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Watch Spineway for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€136,000 €0.0798 Fair Value €0.1743 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range €0.0798 – €136,000 · fair‑value band €0.1182 – €0.2116 · the €0.0980 price screens below the €0.1743 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Spineway in your weekly email

Every Wednesday you see whether Spineway is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Spineway SA designs, develops, and markets a range of surgical implants for spine in France.

Show moreShow less

The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products.

The company was incorporated in 2005 and is headquartered in Ecully, France.

Stock analysis

Spineway (ALSPW) currently trades at €0.0980, while our model-based Fair Value estimate is €0.1743, implying the stock looks roughly 44% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.1182 (bear) to €0.2116 (bull), the price of €0.0980 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Spineway reported revenue of €12.4M in FY2025 versus €4.3M in FY2021, a compound +30.5%/yr. Reported net income was −€2.2M in FY2025.

Key figures

Market cap €3.5M Micro · P/S ratio 0.25 · EPS (TTM) €−0.0600 · Net margin −18.2% · Return on equity −9.5% · Return on assets (EBIT) −14.3% (5-year average) · Operating margin −28.4% · Revenue (TTM) €13.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 78%, ALSPW screens cheaper than that median.

Fair Value models

Bear €0.1182 Fair Value €0.1743 Bull €0.2116
Price €0.0980 · Upside +77.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.1200 €0.1800 €0.2200 55
All 1 models by family
Asset-Based
NCAV (Graham) €0.1200 €0.1800 €0.2200 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 45
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.8%
Start year 2020 (pandemic). Over 10 years: +8.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−43.7% (2020) → −17.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ALSPW, get fair value alerts →

Compare Spineway with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside +77.9% · Top 25%
Profitability
Return on assets −7.6% · Bottom 25%
Net margin (12 months) −18.2% · Bottom 25%
Operating margin (12 months) −28.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.1% · Below median
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.15× · Cheapest 25%
P/S (12 months) 0.27× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 17
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $89.08 $131.27 +47% vs ALSPW
EssilorLuxottica Société anonyme EL €184.50 €196.22 +6% vs ALSPW
Intuitive Surgical, Inc ISRG $443.59 $353.90 −20% vs ALSPW
Medline Inc MDLN $39.47 $28.59 −28% vs ALSPW
Alcon Inc ALC CHF 62.14 CHF 35.08 −44% vs ALSPW
Becton, Dickinson and Company BDX $218.03 $97.80 −55% vs ALSPW
Straumann Holding STMN CHF 108.75 CHF 45.50 −58% vs ALSPW
West Pharmaceutical Services, Inc WST $416.42 $139.22 −67% vs ALSPW
Sartorius Stedim Biotech S.A DIM €225.20 €54.82 −76% vs ALSPW
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs ALSPW

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Spineway: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Spineway Fair Value". https://www.fairvalue-calculator.com/stock/ALSPW

Frequently asked questions

Is Spineway (ALSPW) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of €0.1743 versus a price of €0.0980, about +78% upside (undervalued).
What is the fair value of ALSPW?
Our model-based fair value for Spineway is €0.1743 (as of Nov 12, 2026), built from audited fundamentals. The current price: €0.0980.
What is the quality score of ALSPW?
Spineway has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Spineway (ALSPW)?
Our model-based price target is the fair value of €0.1743 (as of Nov 12, 2026) from 1 valuation models. Cautious scenario €0.1182, optimistic scenario €0.2116. It is a calculation from audited fundamentals, not an analyst target.
What is the Spineway stock forecast for 2026?
Our models put fair value at €0.1743, about +78% upside versus a price of €0.0980 (undervalued). Cautious scenario €0.1182, optimistic scenario €0.2116. The calculation is refreshed regularly with new filings.
What is the revenue of Spineway (ALSPW)?
Spineway reported trailing-twelve-month revenue of about €13.0M (latest available figure, as of Nov 12, 2026).
What is the intrinsic value of Spineway (ALSPW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Spineway it is €0.1743 per share (as of Nov 12, 2026), against a price of €0.0980. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Spineway stock overvalued or undervalued in 2026?
As of Nov 12, 2026, ALSPW trades below its calculated fair value: price €0.0980, fair value €0.1743, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALSPW?
No. The price is what the market pays today (€0.0980); the fair value is what the company's own numbers justify (€0.1743). For Spineway the two are €0.0763 per share apart. That gap is exactly why we show both numbers side by side.
How much is Spineway worth?
The market values Spineway at about €3.5M (market capitalisation, as of Nov 12, 2026). Per share that is €0.0980; our models calculate a fair value of €0.1743 per share.
What do the bullish and bearish scenarios say about ALSPW?
Our models span a range for Spineway: cautious scenario €0.1182, base €0.1743, optimistic €0.2116 per share (as of Nov 12, 2026, price €0.0980). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Spineway (ALSPW)?
Balance-sheet figures for Spineway (as of Nov 12, 2026): return on equity −9.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ALSPW from its 52-week high?
Spineway trades at €0.0980, about 49% below its 52-week high of €0.1920 and 14% above the low of €0.0858 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of €0.1743 is for.
Which stocks are comparable to Spineway?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Spineway stock attractive at the current price?
The data as of Nov 12, 2026: price €0.0980, calculated fair value €0.1743 (+78%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALSPW calculated?
We run Spineway through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.1743 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Spineway currently trades 44% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Spineway (ALSPW)?
The closing price on Nov 16, 2026 was €0.0980. Our model-based fair value is €0.1743, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Spineway right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€0.1182). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Spineway

How large is the market capitalisation of Spineway (ALSPW)?
The market capitalisation of Spineway is €3.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Spineway (ALSPW)?
The price-to-sales ratio of Spineway is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Spineway (ALSPW)?
Earnings per share at Spineway are €−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Spineway (ALSPW)?
The net margin of Spineway is −18.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Spineway (ALSPW)?
The return on equity (ROE) of Spineway is −9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Spineway (ALSPW)?
On an EBIT basis the return on assets of Spineway is −14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Spineway (ALSPW)?
The operating margin of Spineway is −28.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Spineway (ALSPW)?
Revenue at Spineway is down 0.1% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Spineway (ALSPW) generate?
The free cash flow of Spineway is −€163K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Spineway (ALSPW) hold?
Spineway holds more cash than debt, €2.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Spineway in the live analysis

One click puts Spineway on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.